Role of cancer stem cells related molecules in oral squamous cell carcinoma

肿瘤干细胞相关分子在口腔鳞癌中的作用

基本信息

  • 批准号:
    22592246
  • 负责人:
  • 金额:
    $ 2.91万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2010
  • 资助国家:
    日本
  • 起止时间:
    2010 至 2012
  • 项目状态:
    已结题

项目摘要

Oral squamous cell carcinoma (OSCC) include cellular heterogeneity, as would be expected if they arose from dysregulated stem or progenitor cells as opposed to the simple clonal expansion of a mutated cell; however, stemness molecule expression levels and distribution remain unclear. To overcome this problem, stemness molecule expressions were determined in OSCC as well as their properties and prognosis. Two chromatin regulators, Bmi-1 and Hmga2, were identified in 12 tumors region and background pair cases of OSCC by microarray. Both molecules are known to promote stem cell self-renewal by negatively regulating the expressions of Ink4a and Arf tumor suppressors. The expression levels were analyzed in 38 pair cases of OSCC by Qrt-PCR and in 91 cases of the same stage of tongue SCC. Despite a similar target, Bmi-1 protein was expressed in an early cancerous region and HMGA2 protein was expressed in a more progressed region. Likewise, Bmi1-expressing tumor had no significance with regard to overall survival (P = 0.67), while HMGA2-expressing tumors had decreased overall survival (P = 0.05). Qrt-PCR analyses also correlated with protein levels. These findings suggest that Bmi-1 is an early detection marker to distinguish cancerous from non-cancerous regions, while HMGA2 is presumed to be a tumor prognosis marker. Among our OSCC analyses, these stemness molecules expressed not so many primitive rare cells in the tumor as almost all other cells in the tumor. OSCC cells with high expression of stemness molecules should partially behave exactly like stem cells.
口服鳞状细胞癌(OSCC)包括细胞异质性,如果它们是由茎或祖细胞失调而不是突变细胞的简单克隆膨胀而产生的,那是预期的。但是,干性分子表达水平和分布尚不清楚。为了克服这个问题,在OSCC及其特性和预后确定了干分子表达式。通过微阵列在12个肿瘤区域和OSCC的背景对病例中鉴定了两个染色质调节剂BMI-1和HMGA2。已知这两个分子都通过负调节Ink4a和ARF肿瘤抑制剂的表达来促进干细胞自我更新。在QRT-PCR和91例同一舌scc的情况下,分析了38对OSCC的表达水平。尽管有类似的靶标,但BMI-1蛋白在早期的癌变区域表达,HMGA2蛋白在进步的区域表达。同样,表达BMI1的肿瘤在总体存活方面没有显着性(P = 0.67),而表达HMGA2的肿瘤的总生存率降低(P = 0.05)。 QRT-PCR分析也与蛋白质水平相关。这些发现表明,BMI-1是将癌性与非癌区区分开的早期检测标记,而HMGA2被认为是肿瘤预后标记。在我们的OSCC分析中,这些干性分子在肿瘤中表达的原始稀有细胞不如肿瘤中的几乎所有其他细胞。具有高干性分子表达高表达的OSCC细胞应部分表现与干细胞一样。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Involvement of hepatocellular carcinoma biomarker, cyclase-associated protein 2 in zebrafish body development and cancer progression
  • DOI:
    10.1016/j.yexcr.2012.09.013
  • 发表时间:
    2013-01-01
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Effendi, Kathryn;Yamazaki, Ken;Sakamoto, Michiie
  • 通讯作者:
    Sakamoto, Michiie
歯周基本治療における細菌叢変化と治療の指標となる細菌の検討
检查牙周基础治疗中细菌菌群的变化以及作为治疗指标的细菌
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shintani S;Hatori,M Toyoshima T;Kurihara Y;Kurokawa Y;Nakahira H;Ito T;Shirota T;金子明寛,織田洋武,伊藤公一,小林寅吉,山崎浩史,松野智宣,佐藤田鶴子,佐藤聡
  • 通讯作者:
    金子明寛,織田洋武,伊藤公一,小林寅吉,山崎浩史,松野智宣,佐藤田鶴子,佐藤聡
化学療法が奏功した耳下腺上皮筋上皮癌肺転移症例
化疗成功治愈腮腺肌上皮癌肺转移一例。
  • DOI:
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Koizumi M.;山崎浩史
  • 通讯作者:
    山崎浩史
Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells & fibroblasts for mammalian internal organs, and their vasculature Rinkevich Y
产生平滑肌细胞的间皮前体谱系的鉴定和前瞻性分离
Xenografted Human Amniotic Membrane-Derived Mesenchymal Stem Cells Are Immunologically Tolerated and Transdifferentiated Into Cardiomyocytes
  • DOI:
    10.1161/circresaha.109.205260
  • 发表时间:
    2010-05-28
  • 期刊:
  • 影响因子:
    20.1
  • 作者:
    Tsuji, Hiroko;Miyoshi, Shunichiro;Umezawa, Akihiro
  • 通讯作者:
    Umezawa, Akihiro
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAMAZAKI Hiroshi其他文献

YAMAZAKI Hiroshi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAMAZAKI Hiroshi', 18)}}的其他基金

Relevance to bioactivation and toxicity of thalidomide, pomalidomide, and lenalidomide by human cytochrome P450 3A enzymes in cultured placental cells and humanized-liver mice
培养胎盘细胞和人源化肝小鼠中人细胞色素 P450 3A 酶与沙利度胺、泊马度胺和来那度胺生物活性和毒性的相关性
  • 批准号:
    17K08425
  • 财政年份:
    2017
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of resistance to molecularly targeted drugs for oral squamous cell carcinoma and investigation of countermeasures
口腔鳞癌分子靶向药物耐药机制及对策研究
  • 批准号:
    16K11732
  • 财政年份:
    2016
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of Effective Markers for Resistance of Oral Squamous Cell Carcinoma to Molecular-targeting Drugs
口腔鳞状细胞癌分子靶向药物耐药性有效标志物的开发
  • 批准号:
    25463120
  • 财政年份:
    2013
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Thalidomide increases cytochrome P450 activity and drug metabolism in liver through direct activation of nuclear receptor CAR and PXR
沙利度胺通过直接激活核受体 CAR 和 PXR 增加肝脏细胞色素 P450 活性和药物代谢
  • 批准号:
    23590200
  • 财政年份:
    2011
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
evaluationofeffectivenessoftheobjectiveexaminationforautism indeafchildren
聋儿自闭症客观检查效果评价
  • 批准号:
    22791642
  • 财政年份:
    2010
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Molecular mechanism of chemical-induced toxicity in fetal livers
化学品致胎儿肝脏毒性的分子机制
  • 批准号:
    17390034
  • 财政年份:
    2005
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular Mechanisms of Toxic Expression Induced by Endocrine Disruptors via AHR
内分泌干​​扰物通过 AHR 诱导毒性表达的分子机制
  • 批准号:
    15390040
  • 财政年份:
    2003
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study on the separation of rac and meso isomers and the reactivity of group 4 bridged metallocene complexes
外消旋和内消旋异构体的分离及第4族桥联茂金属配合物的反应性研究
  • 批准号:
    11640544
  • 财政年份:
    1999
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PREDICTION OF DRUG DISPOSITION BY HUMAN DRUG METABOLIZING ENZYMES
通过人体药物代谢酶预测药物分布
  • 批准号:
    11557191
  • 财政年份:
    1999
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
Creation of Substitution Labile Pyrazolylborate Metal Complexes
取代不稳定的吡唑基硼酸盐金属配合物的制备
  • 批准号:
    09640675
  • 财政年份:
    1997
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Development of novel evaluation method to investigate lung carcinogenicity by a comprehensive analysis of drug-metabolizing enzyme expressions in human bronchial epithelium.
通过综合分析人支气管上皮中药物代谢酶的表达,开发新的评估方法来研究肺癌的致癌性。
  • 批准号:
    18K08805
  • 财政年份:
    2018
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
iPSC特異的糖鎖認識レクチンの癌幹細胞マーカーとしての有用性と診断治療への応用
iPSC 特异性糖链识别凝集素作为癌症干细胞标记物的用途及其在诊断治疗中的应用
  • 批准号:
    18K17199
  • 财政年份:
    2018
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Biological role of CD280 in cancer metastasis-initiating cell
CD280在癌症转移起始细胞中的生物学作用
  • 批准号:
    16H04697
  • 财政年份:
    2016
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Study of the prevention and complementary treatment of advanced cancer: Examination of presymptomatic diagnosis and reactivation of cancer suppression mechanism
晚期癌症的预防和补充治疗研究:症状前诊断检查和癌症抑制机制的重新激活
  • 批准号:
    16K09258
  • 财政年份:
    2016
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of biological properties and acquisition of tumor-specific marker for micropapillary predominant lung adenocarcinoma
阐明微乳头状肺腺癌的生物学特性并获得肿瘤特异性标志物
  • 批准号:
    15K21359
  • 财政年份:
    2015
  • 资助金额:
    $ 2.91万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了